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Abstract. Investigations into mechanisms that restrict
the recovery of functions after an injury to the brain or
the spinal cord have led to the discovery of specific
neurite growth inhibitory factors in the adult central
nervous system (CNS) of mammals. Blocking their
growth-suppressive function resulted in disinhibition
of axonal growth, i.e. growth of cultured neurons on
inhibitory CNS tissue in vitro and regeneration of
injured axons in vivo. The enhanced regenerative and
compensatory fibre growth was often accompanied by
a substantial improvement in the functional recovery
after CNS injury. The first clinical studies to assess the
therapeutic potential of compounds that neutralize
growth inhibitors or interfere with their downstream
signalling are currently in progress. This review
discusses recent advances in the understanding of
how the founder molecule Nogo-A and other glial-
derived growth inhibitors restrict the regeneration
and repair of disrupted neuronal circuits, thus limiting
the functional recovery after CNS injuries.
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Introduction
In mammals, an injury to the adult central nervous
system leads to irreversible functional impairments.
For example, after a cervical spinal cord injury (SCI),
the ability towalk or to grasp an object is impaired and
there is little recovery of these motor functions
following the acute phase after large injuries. Sim-
ilarly, after stroke, various functions are impaired
depending on which brain regions are damaged. After
large strokes, substantial recovery is rare and func-
tional deficits usually persist for the rest of life. This
lack of significant functional recovery after CNS
injury corresponds with the failure of mature central
neurons to effectively regenerate axons. Lesioned
nerve fibres usually retract and form dystrophic end
bulbs [1]. Occasionally, the proximal stumps of cut
axons start to grow short sprouts but this sprouting
response comes to a halt. The sprouting collaterals are
not able to grow significantly and often retract [1, 2].
This is in sharp contrast to the response of injured
axons in the peripheral nervous system, which regen-
erate vigorously over long distances and re-establish
functioning synaptic contacts with peripheral muscles,
a process which can lead to functional restoration.
This observation inspired the landmark experiments
of Aguayo and colleagues in the early 1980s [3]: they
showed that after spinal cord injury, CNS axons
readily grew into a peripheral nerve graft transplanted* Corresponding author.
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into the wound. This demonstrated, for the first time,
that adult, injured central neurons are able to
regenerate long axons under favourable conditions
(including basal lamina tubes and Schwann-cell-
derived trophic factors) of the peripheral-nerve mi-
croenvironment.
In the late 1980s, our laboratory undertook experi-
ments to investigate the molecular differences be-
tween central and peripheral nerve tissue. We found
that explanted, cultured dorsal root ganglion neurons
grew into explants of sciatic nerves, but not into optic
nerves despite the presence of high concentrations of
trophic factors [4]. Subsequently, myelin extracted
from peripheral nerves was shown to be growth
permissive whereas CNS myelin strongly inhibited
nerve growth [5]. We went on to isolate a membrane
protein from CNS myelin that strongly inhibited
neurite growth, IN-250, which is now called Nogo-
A [5–7]. Antibodies raised against this inhibitory
protein neutralized the growth-restricting properties
of oligodendrocyte myelin in vitro [8]. However, the
most encouraging results achieved with these anti-
bodies was the substantial regeneration of cut fibre
tracts in vivo [9]. Importantly, this increased regener-
ation was accompanied by an impressive recovery of
lost motor function [10, 11].
The discovery and characterization of myelin-associ-
ated neurite growth inhibitory proteins, in particular
Nogo-A, has opened the door to a new field in
regeneration research. In the wake of this break-
through, other molecules were found to suppress
neurite growth in the adult CNS. Most of them are
located in the myelin sheaths of oligodendrocytes or
are secreted into the extracellular matrix after injury.
Nogo-A
Nogo-A, -B and -C are splice variants of the nogo gene
that was identified on the basis of peptide sequences of
IN-220/250, isolated fromCNSmyelin [6, 7, 12, 13]. All
three Nogo isoforms share a common carboxyl termi-
nus of 188 amino acids which contains two long
hydrophobic domains and a short loop of 66 amino
acids between the two hydrophobic domains, called
Nogo-66. The common C-terminus is a reticulon
homology domain (RHD) and assigns the Nogo gene
to the Reticulon protein family, with Nogo being
Reticulon 4 (RTN4).However, the commonNogo-A/B
N-terminus and the large, 800-amino-acid-long Nogo-
A-specific region are unique to Nogo and have no
homology to the RTN genes. Reticulons are highly
conserved, and reticulon-like genes occur in all eukar-
yotes. Nogo-A, like other reticulons, contains an
endoplasmatic reticulum (ER) retention motif and is
highly enriched in the ER, in addition to its location in
the cell membrane [7, 8, 12–14]. A recent report
suggests that Nogo/RTN4might be involved in shaping
the tubular morphology of the ER [15].
Although a large part of Nogo-A is found intra-
cellularly, it is also present on the cell surface and at
least three active sites are exposed to the extracellular
space: the Nogo-66 domain, which is close to the C-
terminus and common to all three Nogo isoforms,
inhibits neurite growth and induces growth cone
collaps [12, 16]. A second active site (also called the
central inhibitory domain) is located within the large
800-amino-acid Nogo-A-specific domain and strongly
inhibits neurite outgrowth and cell spreading and
induces growth cone collapse [16]. The third active
site is found in the Nogo-A/B-specific N-terminus
which inhibits spreading of cultured fibroblast [16]
and was recently shown to promote adhesion of
vascular cells and to stimulate endothelial cell migra-
tion [17, 18].
The glycoprotein NgR, which is widely expressed in
many neurons, has been characterized as a receptor
subunit that binds to the Nogo-66 site [19–21]. NgR is
a GPI-linked cell surface protein that lacks an intra-
cellular domain and requires either p75 [22, 23] or
TROY [24, 25] as co-receptors to mediate signal
transduction across the cell membrane. Both are
transmembrane proteins of the tumour necrosis factor
receptor (TNFR) family. Another co-receptor,
LINGO-1, acts as an adaptor protein and seems to
be required for Nogo-A signalling [26]. Interestingly,
two other myelin-associated growth inhibitors, MAG
andOMgp, bind toNgRwith high affinity as well. This
means that three structurally unrelated myelin-asso-
ciated inhibitory molecules, Nogo-A, MAG and
OMgp, converge on a single receptor complex and
share a common intracellular signalling pathway [22,
27–30].
Several in vitro and in vivo observations indicate that
another yet unknown receptor mechanism may medi-
ate Nogo-A-specific signalling. Although the Nogo-
A-specific central region does not bind to NgR, it
inhibits neurite outgrowth and prevents spreading of
different cell types [16]. Moreover, corticospinal tract
neurons of ngr–/– or p75–/– mice do not regenerate after
SCI [31–33] but regenerate vigorously after applica-
tion of antibodies directed against the Nogo-A-
specific domain in vivo (see below), indicating that
another receptor or an additional receptor subunit
may be of importance for the in vivo suppression of
axonal growth.
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Nogo-A is expressed in oligodendrocytemyelin and in
some subpopulations of neurons
Nogo-A is highly expressed in oligodendrocytes of
higher vertebrates, where it localizes mainly to the
outer and innermost adaxonal myelin sheath (i.e. at
the axon-oligodendrocyte contact zone) and to syn-
aptic sites [34, 35].
The time of myelination of different pathways coin-
cides with the age at which their regenerative capa-
bility is lost, pointing to the crucial contribution of the
myelin-associated inhibitors such as Nogo-A in form-
ing the growth-suppressive environment of the adult
CNS [36]. During development, oligodendrocyte
Nogo-A expression follows the course of myelination:
in the developing cerebellum, for example, nogo-a
mRNA first appears in oligodendrocytes in deep
cerebellar regions at P5 and later on, at P9, Nogo-A-
positive oligodendrocytes are found towards the distal
ends of the folia in the white matter, correlating with
the course of myelination [34, 37].
During development, Nogo-A is also expressed in
subpopulations of neurons [34, 38–43], whereas in the
adult CNS, neuronal Nogo-A is down-regulated in
most of these regions. Neuronal expression ofNogo-A
is tightly regulated during development; for example,
olfactory receptor neurons and cerebellar granule
cells were shown to have high levels of Nogo-A
protein or mRNA during differentiation and migra-
tion, but after maturation, Nogo-A was virtually
absent [34, 39]. In growing axons, Nogo-A preferen-
tially localizes to the growth cone and to axonal
branching points [39, 41, 43, 44]. Furthermore, radial
glia cells, which are crucial for cortical development,
express high levels of Nogo-A [43].
In contrast to mammals, Nogo-A is not found in the
CNS myelin of lower vertebrates like fish or sala-
mander [45, 46], whose CNS has a much higher
regenerative potential [47–51]. Salamander, for ex-
ample, can completely regenerate an injured spinal
cordwith full restoration of functions [50]. In contrast,
frogs do express Nogo-A in myelin [46]. Accordingly,
their regenerative potential is limited, and adult frogs
do not recover from spinal cord transection [52].
Interestingly, Nogo-A expression levels are also
known to be altered in a number of CNS diseases.
For example, in amyotrophic lateral sclerosis (ALS),
Nogo-A is up-regulated in muscles and spinal cord
motoneurons [53] and might be involved in the
pathophysiology of the disease [54]. The expression
of Nogo-A in muscle tissue could also be used as an
early diagnostic [53] and prognostic [55] marker for
ALS. Furthermore, soluble Nogo-A fragments are
found in the cerebrospinal fluid of patients with
multiple sclerosis (MS) [56, 57]. In experimental
autoimmune encephalomyelitis (EAE), a widely
used animal model for MS, vaccination against a
Nogo-A fragment or passive immunization with anti-
Nogo-A antibodies attenuate clinical signs, demyeli-
nation and axonal damage [58, 59].
After brain or spinal cord trauma, overall Nogo-A
protein or mRNA levels are mostly unaltered [34, 38,
41]. After the Wallerian degeneration of axons distal
to an injury site, the myelin sheaths persist for a long
time in the CNS. Indeed, Nogo-Awas still detectable
in degenerated fibre tracts of human spinal cord 3
years after spinal cord injury [60].
The intracellular signalling pathways of Nogo-A
involve RhoA and Ca2+
CNS neurons respond to Nogo-A with growth cone
collapse and the arrest of neurite growth, suggesting
an intracellular signalling mechanism that ultimately
acts on cytoskeletal dynamics. Activation of RhoA
seems to be a major downstream signalling mecha-
nism of Nogo-A [61–64]. RhoA is a GTPase of the
Rho family and is known for its central role in the
signal transduction of axonal guidance molecules
during development. Rho-A together with two other
members of the same family, Rac1 andCdc42, interact
with a series of downstream effectors to regulate the
dynamics of the actin cytoskeleton [for reviews see
refs. 65–68]. Active RhoA activates Rho kinase
(ROCK) which in turn can phosphorylate several
other effectors. Injured axons are able to grow on an
inhibitorymyelin substrate whenRhoA or ROCK are
inactivated [62–64]. Further downstream signalling
may involve the phosphorylation of cofilin by LIM
kinase [69].
Nogo-A also initiates a rise in intracellular calcium,
which mediates collapse of growth cones [23, 70]. Two
additional signalmediators were found to be activated
aswell: protein kinaseC (PKC) [71, 72] and epidermal
growth factor receptor (EGFR) [73]. These pathways
may act in parallel or in sequence with RhoA.
Interestingly, Nogo-A shares some of its downstream
effectors with other myelin associated inhibitors of
neurite growth as well as with chondroitin sulphate
proteoglycans (see below) [73–76]. Targeting these
downstream effectors of Nogo-A with specific block-
ing compounds therefore prevents the signalling of a
number of different neurite growth inhibitors.
Several other myelin-associated molecules also
suppress neurite growth
Several components of CNS myelin have been shown
to inhibit regrowth of injured neurons. Myelin-asso-
ciated glycoprotein (MAG) [77, 78] and oligodendro-
cyte myelin glycoprotein (OMgp) [27] are enriched in
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oligodendrocytes. Although both are structurally
unrelated to Nogo-A, they can bind to the NgR/p75/
Lingo-1 receptor complex. The blockade of this
pathway promotes neurite growth in vitro, but there
is no evidence so far that acute in vivo neutralization
of MAG or OMgp or gene knockout leads to
regeneration or improves functional recovery. Versi-
can V2 and brevican, both CSPGs, are constitutively
present in myelin and also suppress neurite growth
[79, 80]. In addition, some repulsive axon guidance
cues that play a role in development continue to be
expressed in oligodendrocytes in adult animals and
have been implicated as inhibitors of axonal regener-
ation. Ephrin B3, best known for its function as a
midline repellent for growing corticospinal tract
(CST) fibres during development, is expressed in
myelinating oligodendrocytes in adult mammals and
strongly inhibits axonal growth in vitro [81]. Mice
which lack EphA4, a receptor for Ephrin B3, show
increased axonal regeneration in vivo [82]. Another
regulator of axonal pathfinding during development,
Semaphorin 4D, is also present in myelinating oligo-
dendrocytes and inhibits neurite growth [83].
The glial scar also contains growth-inhibitory
molecules that impede the regeneration of cut axons
through the lesion site
Myelin is not the only source of neurite growth
inhibition in the adult CNS. CNS injuries trigger a
cascade of cellular, vascular andmolecular events that
eventually lead to the formation of a glial scar: the
disruption of the blood-brain barrier results in the
recruitment of inflammatory cells, neutrophils and
macrophages that invade the disrupted tissue and,
together with activated resident microglia cells, start
to phagocytose cell debris. They release a wealth of
inflammatory mediators such as cytokines and pros-
taglandins, which in turn attract more inflammatory
cells, including T cells, to the injury site and together
produce a complex concert of cellular and molecular
factors that can be supportive or inhibitory for neurite
growth [for reviews on inflammation and regeneration
see refs. 36, 84].
At the same time, glial cells, notably activated
astrocytes and oligodendrocyte precursor cells, to-
gether with invading meningeal cells start to produce
chondroitin sulphate proteoglycans (CSPGs) and
release them into the extracellular space [85]. Differ-
ent species of CSPGs, such as NG2, neurocan,
versican, phosphacan and brevican [79, 86–90] are
strong inhibitors of neurite growth and accumulate at
and around the lesion site within days after an injury.
These secretedCSPGs are an important component of
the glial scar and may persist for months [91, 92],
impeding sprouting and regenerating axons from
crossing the lesion site.
Accumulated CSPGs can be enzymatically degraded
by repeatedly injecting bacterial chondroitinase ABC
into the injured tissue [93]. This elimination of
inhibitory CSPGs was shown to increase effectively
the regeneration of cut axons through the glial scar
and thus improve the recovery of motor and sensory
functions [93]. Using the GFAP promotor to trans-
genically express chondroitinase ABC in astrocytes
led to increased growth of CST axons into the lesion
site but did not yield an improved recovery of motor
functions [94] [The role of CSPGs after CNS injury is
reviewed in refs. 85, 95].
Myelin-associated inhibitors and CSPGs stabilize
existing connections and suppress plasticity in the
mature CNS
The occurrence of different inhibitory molecules in
the CNS of adult mammals suggests that they play a
vital role. Increasing evidence indicates that myelin
and its associated inhibitors of axonal growth control
and restrict fibre growth in the adult CNS. For
example, the onset of myelination correlates with
the postnatal decline in the plastic potential in various
axonal pathways as shown by the decline of the
plasticity marker GAP-43 concurrently with myelina-
tion [96]. Moreover, the CNS remains permissive for
neurite growth if myelination is blocked by neonatal
X-ray irradiation [97].
Myelin andmyelin-associated inhibitors appear in the
CNS after the completion of axon growth. Intrigu-
ingly, they might actually be involved in terminating
the neurite growth phase during postnatal CNS
development. Following axonal pathfinding and ini-
tial circuit formation in early development, a second,
activity-dependent process adjusts and fine-tunes the
neuronal circuits in critical periods during early
postnatal life. These critical periods, characterized by
a high plasticity of connections, are restricted to well-
defined time windows in early life. For example,
ocular dominance columns in the visual cortex are
fine-tuned during a short postnatal time period:
during this critical period, monocular deprivation by
experimentally closing one eye leads to the expansion
of the ocular dominance columns of the contralateral,
non-deprived eye [98].
Two papers have shown that Nogo-A, via its receptor
NgR, and CSPGs are involved in closing the critical
period for ocular dominance in the visual cortex.
Enzymatic degradation of CSPGswith chondroitinase
ABC was shown to restitute plasticity for monocular
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deprivation in adult rats, leading to a shift of ocular
dominance to the non-deprived eye after unilateral lid
suture [99]. Genetic deletion of Nogo-A/B or the
Nogo receptor subunit NgR was found to extend the
closure of the critical period for monocular depriva-
tion in young adultmice [100]. It seems, therefore, that
Nogo and CSPGs actively contribute to the consol-
idation of neuronal circuits during CNS maturation.
They restrict plasticity and may prevent axons from
aberrant growth in the adult CNS [96, 101, 102]. The
lack of axonal regeneration would therefore be the
price to pay for the stabilization of a complex nervous
system [96, 102–104].
Blocking Nogo-A function after SCI
The consequences of SCI are complex: vast numbers
of axons that carry sensory information from the
spinal cord to the brain and motor and autonomic
system commands from the brain to the spinal cord are
partly or, in rare cases, completely disconnected from
their specific targets. At the level of the injury,
interneurons and motoneurons are destroyed. Yet,
about half of spinal-cord-injured patients in western
countries show some limited recovery in the first
months after the injury [105]. Patients with lesions
that do not completely interrupt all ascending and
descending pathways aremore likely to spontaneously
recover some of the lost functions. These functional
improvements, however, are variable and depend on
the lesion anatomy. Most patients have to cope with
permanent functional deficits. Depending on the level
and the severity of the injury, many patients suffer
from motor and sensory deficits and malfunctions
such as pain and spasticity for the rest of their life.
Often, apparently small functional improvements, e.g.
regaining some hand function or being able to stand
up from the wheelchair and support the own weight,
can mean a lot in the daily life of a victim of SCI and
may decide between complete dependence or living in
autonomy.
Such spontaneous functional improvements are large-
ly due to adaptive changes in the neuronal circuitries
of the brain and the spinal cord. Axotomized neurons
around the lesion were shown to up-regulate growth
proteins such as GAP-43, and some transected axons
may sprout and grow collaterals and may form new
functional connections [106, 107].
However, reorganization of the injured CNS is
limited, due in part to restrictions imposed by the
inhibitory CNS environment. Attempts of axons to
regenerate are transitory and abortive; they eventu-
ally form dystrophic endbulbs and growth-associated
proteins are down-regulated after a few days [36].
Such observations have led to the conclusion that the
lack of substantial functional recovery after large
brain or spinal cord injuries is caused by ineffective
regeneration of lesioned axons, the regeneration
being limited by neurite growth inhibitors. The
immediate questions brought about by the discovery
of inhibitory factors and in particular the protein
Nogo-A were: (1) Would the functional blockade of
Nogo-A signalling after CNS injury increase the
otherwise abortive regenerative response and allow
axons to regenerate over longer distances? (2) Could
regeneration together with the potential increase in
compensatory fibre growth and circuit plasticity lead
to improved functional recovery?
Experiments from various laboratories over more
than 10 years suggest that the answer to both questions
is yes. Neutralizing Nogo-A either by applying func-
tion-blocking antibodies directed against the N-ter-
minal region ofNogo-Aor by interferingwithNogo-A
receptors or signalling pathways boosts the regener-
ative response of injured adult CNS tracts, stimulates
compensatory fibre growth and improves the recovery
of lost functions [9–11, 62, 108–111].
Four different lines of transgenic animals lacking
Nogo-A, Nogo-A and -B or Nogo-A, -B and -C
generated by three independent laboratories yielded
somewhat conflicting results [112]. Whereas the
Nogo-A [113] and the Nogo-A and -B [114] knockout
lines showed an increased regenerative phenotype,
with an increased number of CST fibres growing from
the end of the severed CST towards the lesion site in
the former, and fibres regenerating into distal cord
segments in the latter, the Nogo-A and -B and Nogo-
A, -B and -C knockoutmice of the third laboratory did
not seem to show increased regeneration [115].
Follow-up studies showed that the genetic background
of different mouse lines [116], compensatory up-
regulation of other Nogo proteins [113] and the lesion
paradigms used [117] may account for some of the
discrepancies in the findings between the different
lines.
Recently, Steward et al. [118] argued that the
increased regeneration in the Nogo-A/B knockout
mice described by Kim et al. [114] might in part be
based on artefactual labelling of axons due to
accidental injection or leakage of the tracer into the
cerebrospinal fluid in the cerebral ventricle. In
response, Cafferty et al. [119] pointed out that this
labelling artefact was rare (5% of traced mice) and
the vast majority of the Nogo-A/B knockout mice
used for their study bore no resemblance to the
labelling pattern of Steward. If the rare mice with
such a pattern were excluded from the axon counts,
the same statistically valid conclusions remained
[119]. In our laboratory, such artefactual labelling of
Cell.Mol. Life Sci. Vol. 65, 2008 Review Article 165
axons resulting from incorrect tracing techniques has
never been observed.
After large but incomplete SCI and treatment with
anti-Nogo-A antibodies, two principal axonal repair
mechanisms were observed. Using reconstructions
from uninterrupted serial section series, cut axons
were seen to regenerate around and beyond the lesion
site and to grow through the denervated spinal cord
for long distances (typicallymore than 1–2mm). They
crossed the injury site on bridges of spared tissue and
could form extensive terminal arbours in the caudal
spinal cord. Corticospinal and serotonergic fibres
were studied most intensively [9, 10, 108, 120, 121]
(Fig. 1).
Alternatively, damaged and/or spared axons were
observed to sprout collaterals above and below the
injury site. These fibres are typically short (up to
1 mm) and can innervate nearby targets, e.g. areas that
were denervated by the lesion. This repair mechanism
is referred to as collateral or compensatory sprouting
(Fig. 2). Belowwedescribe inmore detail the recovery
process mediated by the neutralization of Nogo-A.
Damaged CNS fibres regenerate after blocking
Nogo-A function
In 1990, Schnell and Schwab [9] reported that
neutralizing Nogo-A with function-blocking mono-
clonal antibodies in rats after an incomplete exper-
imental SCI increased the regeneration of cut axons.
They implanted anti-Nogo-A-antibody-producing hy-
bridoma cells into the brain of young, adult rats and
transected the dorsal two-thirds of the thoracic spinal
cord, including the CST. As a consequence of the
treatment, the CST, a major motor and sensory
pathway that originates in the sensorimotor cortex
and projects to the spinal cord, regenerated up to
11 mm beyond the injury site (Fig. 1d). In contrast,
control animals, treated with antibodies against an
unrelated protein, rarely regenerated their CST fibres
beyond 0.5–1 mm.
These experiments were repeated in a more clinically
relevant setting. Specifically, highly purified mono-
clonal antibodies directed against the N-terminal
region of Nogo-Awere applied via a small intrathecal
lumbar catheter directly into the cerebrospinal fluid.
The results were similar: the number of regenerated
CST fibreswasmuchhigher in anti-Nogo-A-antibody-
treated animals than in control animals [120]. The
antibodies that have been used in these studies
specifically recognize the Nogo-A-specific domain in
the middle of the Nogo-A molecule, thereby blocking
the binding of Nogo-A with a putative Nogo-A-
specific receptor (see above). Due to the large size of
IgG antibodies, steric blockade of the Nogo-A-NgR
interaction could occur as well. In addition, antibody-
induced internalization and subsequent degradation
of cell surface Nogo-A decreases the total tissue levels
of Nogo-A and may indirectly contribute to the
plasticity-enhancing effects of intrathecally applied
anti-Nogo-A antibodies in CNS-injured animals
[122].
Other approaches to block Nogo functions, e.g. by
blocking NgR with a blocking peptide (NEP1–40) or
by targeting downstream effectors that are shared by
other neurite growth inhibitors, e.g. RhoA and
ROCK, with blocking compounds yielded compara-
ble results with respect to CST regeneration [62, 108,
111] (Fig. 1d).
Figure 1. Regenerative axon growth after different CNS lesion
paradigms is increased after anti-Nogo-A antibody or NgR
antagonist treatment. Lesion sites are indicated with black arrow
heads. Red= regenerated axons. (a) Cholinergic axons regenerate
after damage to the septo-hippocampal projection and reinervate
their original terminal areas in the hippocampus (Hip) [124].
Blue=cut axons; Cc, corpus callosum. (b) Cochlear fibres,
originating from the ganglion spirale (Gs) in the cochlea, regen-
erate after an auditory nerve transection; some fibres reach their
correct target nuclei in the brainstem (Bs) [127]. Blue=cut axons;
Cn, cochlear nuclei. (c)Retinal ganglion cell axons regenerate after
a freeze-crush lesion of the optic nerve after combined fibroblast
growth factor or brain-derived neurotrophic factor and anti-Nogo-
Aantibody treatment [126] or after suppressingNgRactivitywith a
dominant-negative construct transfected into retinal ganglion cell
axons [125]. Blue=cut axons. (d) Spinal cord: after dorsal bilateral
hemisection of the thoracic spinal cord, cut corticospinal tract
axons (blue) regenerate through bridges of spared tissue and grow
1–2 cm below the lesion site and spared CST axons sprout
collaterals below the lesion site after treatment with anti-Nogo-A
antibodies [9, 120, 121] or blocking NgR [133] or blocking RhoA
and ROCK [62, 111]; lesioned and/or spared 5-HT fibres (grey)
regenerate/sprout vigorously below the injury site [10, 133].
Blue= spared and intact CST axons; green= sprouted fibres; 5-
HT, serotonergic (5-hydroxytryptamine) raphespinal tract.
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So far most studies have focused on the regeneration
of CST neurons because their origin, the sensorimotor
cortex, is readily accessible for neuroanatomical tract
tracing. However, the regenerative potential may not
be equal for different spinal tracts.
Another descending pathway with crucial modulatory
function for motor, sensory and autonomic circuits in
the spinal cord, the serotonergic raphespinal tracts,
also responded vigorously to Nogo-A blocking treat-
ment after a large partial spinal cord lesion: the
density of 5-HT fibres below the injury site recovered
substantially, reaching normal, preinjury levels in
some studies [10, 108, 123] (Fig. 1d). Many fibres
may have regenerated but some may also have
sprouted from intact fibres that were not interrupted
by the injury. Other descending pathways originating
from the brainstem, such as the vestibulospinal and
reticulospinal tract, are crucial for locomotor func-
tions, yet their response to Nogo-A inactivation has
not been studied.
Other important CNS pathways have been studied for
their potential to regenerate after Nogo-A neutrali-
zation. In a paradigm for axonal injury in the hippo-
campus, the regeneration of cut cholinergic septo-
hippocampal axons was boosted substantially by anti-
Nogo-A antibodies [124] (Fig. 1a). Similar results
were found after a crush lesion of the optic nerve.
Suppressing NgR activity with a dominant-negative
NgR construct transfected into retinal ganglion cells
led to an enhanced regeneration of retinal ganglion
cell axons when combined with stimulation by macro-
phage-derived factors [125]. Increased regeneration
of retinal ganglion cells was also seen after application
of anti-Nogo-A antibodies combined with brain-
derived neurotrophic factor [126] (Fig. 1c). Equiva-
lent effects were seen with a recombinant Fab frag-
ment of an anti-Nogo-A antibody after cochlear nerve
lesion: cochlear fibres regenerated substantially, and
some fibres reached their correct target nuclei in the
brainstem. In contrast, control-antibody-treated ani-
mals did not show any comparable recovery [127]
(Fig. 1b).
These studies show that Nogo-A inactivation pro-
motes axonal regeneration of various types of CNS
neurons. Whether qualitative or quantitative differ-
ences exist between neurons and tracts with regard
Figure 2. Plastic changes in corticofugal projections that are induced or increased by anti-Nogo-A antibody treatment after spinal cord
injury (b) and stroke (c). (a) The overview shows the location of the coronal brain and spinal cord sections. The CST and corticostriatal
fibres originating in the left cortex and descending (mainly) in the right half of the spinal cord are in blue, the opposite CST is in black.
Dashed lines indicate the degenerated CST below the disruption site. Red, sprouting axons (b/c 1–5) and dendrites (c5). (b)
Pyramidotomy: a unilateral pyramidotomy (black arrowhead) interrupts selectively the CST on one side at the level of the medulla
oblongata (b2) before it decussates. Above the lesion, the affected CST grows midline crossing collaterals to the red nucleus (b4) and the
basilar pontine nuclei (b3) [11, 130, 131]. In the medulla (b2), the dorsal column nuclei are reinervated [11]. The unlesioned CST sprouts
across the midline in the spinal cord (b1) and reinervates the grey matter after anti-Nogo-A antibody treatment [11]. Similar results were
found in ngr–/– and nogo-a/b–/– mice [117]. (c) stroke: spared corticospinal tract fibres are seen to sprout to the contralateral side that was
denervated by the stroke at several levels. In the mesencephalon (c4) they grow to the contralateral red nucleus, in the pons to the
contralateral basilar pontine nuclei (c3), and in the spinal cord to the contralateral grey matter (c1) [109, 110, 140, 141, 155]. In the
telencephalon (c5), corticofugal fibres increase the innervation of the contralateral dorsal striatum [154]. Apical and basilar dendrites of
contralesional layer V pyramidal neurons arbourize to a greater degree [157].
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to Nogo-A suppression remains to be studied in
detail.
However, regenerated axons as such are effectively
worthless unless they form functional synaptic con-
tacts with appropriate target neurons and integrate
correctly into the deafferentiated circuitries below
the lesion. Indeed, following dorsal bilateral hemi-
section and anti-Nogo-A antibody treatment, regen-
erated axons branched extensively in the grey matter
and formed terminal arbours with numerous vari-
cosities, indicating strongly that they established
synaptic contacts to target neurons below the injury
site [121].
Nevertheless, the often small proportion (typically 5–
10%) of interrupted fibres that eventually by-passed
the lesion site and their variable length (a few
millimeters to 1–2 cm in the rat) indicate that other
factors, like the lack of trophic support or the
inhibitory glial scar, play additional important roles
in preventing axons from regenerating successfully.At
the same time, it suggests that other mechanisms,
especially compensatory ones, may contribute signifi-
cantly to functional recovery after large SCIs.
Damaged and spared fibres sprout above and below
the SCI site after blocking Nogo-A function
Most SCIs are incomplete and leave a proportion of
axonal projections intact. In young postnatal animals,
these spared fibres sprout and form collateral branch-
es below the injury site andmay connect to targets that
have been left denervated by the SCI [128]. Such new
connections are thought to compensate for the lost
connections and thereby contribute to the sponta-
neous functional recovery. The ability to form new
collateral connections declines soon after early post-
natal life and may be related to myelination (see
above) [96, 129]. Blocking a major inhibitory compo-
nent of myelin, Nogo-A, in adult animals, increased
the ability to sprout new collaterals after SCI (Fig. 2).
After a unilateral transection of the CSTat the level of
the medulla oblongata (pyramidotomy), the contrala-
teral spared CST sprouted and grew into the dener-
vated side of the spinal cord after treatment with anti-
Nogo-A antibodies [11] or if nogo-a/b or ngr [117] was
genetically deleted (Fig. 2b). Corticoefferent fibres
from the affected side also sprouted across themidline
and innervated motor and sensory areas in the
contralateral brainstem, including the red nucleus,
basilar pontine nuclei and dorsal column nuclei [11,
130, 131] and formed new synaptic contacts [131]
(Fig. 2b).
If the CST was transected bilaterally (bilateral pyr-
amidotomy), another descending projection, the ru-
brospinal tract, originating in the mesencephalic red
nucleus, started to form new collateral sprouts in the
cervical spinal cord in response to antibodies against
Nogo-A [132]. Red nucleus microstimulation con-
firmed the functionality of these new rubrospinal
connections.
Blocking Nogo-A function improves the recovery of
motor functions after SCI
The increased fibre growth in the lesioned CNS after
therapeutic interventions is promising, but even more
hopeful is the improvement in the recovery of motor
function that is correlated with treatments.
Adult rats show some spontaneous recovery after
large but incomplete spinal cord lesions, which
reaches a plateau after 4–6 weeks. A dorsal bilateral
hemisection of the thoracic spinal cord, for example,
severely affects hindlimb functions, and the functional
recovery is limited. However, if rats were treated with
Nogo-A antibodies, these impaired functions recov-
ered faster and to a larger extent, in particular in
precision tests, e.g. walking on a narrow beam or
crossing a unevenly spaced horizontal ladder. Their
ability to swim or to climb a rope was also reported to
be improved [10, 120, 121]. Similar results were found
when the Nogo receptor subunit NgR was blocked by
the small peptide antagonist NEP 1–40, or when
Nogo-Awas blocked byNgR(319)ecto [108, 133, 134],
or by a soluble antagonist of the NgR co-receptor
LINGO-1 [135]. Targeting intracellular mediators of
Nogo-A signalling was equally effective: blocking
RhoA with C3 transferase or ROCK with a compet-
itive inhibitor (Y-27632) increased the functional
recovery after SCI [111]. The effects of blocking
these downstream effectors may reflect the conse-
quence of inhibiting several neurite growth inhibitors
whose signalling pathways seem to converge to a
certain degree.
Substantial improvements in the CST-dependent
skilled forelimb use after unilateral pyramidotomy
and Nogo-A antibody treatment or knockout have
been observed as well [11, 117] (Fig. 3a).
Importantly, common malfunctions after SCI, like
pain or spasticity or disturbances in behaviour have
not been observed in animals treated with reagents
that block the Nogo-Nogo receptor pathway [33, 120,
136, 137].
Blocking Nogo-A function after stroke and traumatic
brain injury
Equally promising are results gained with animal
models for ischaemic stroke. Neutralizing the
growth-inhibitory environment of the CNS by block-
ing Nogo-A function after experimental stroke
increased greatly the functional recovery in adult
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rats. Middle cerebral artery occlusion (MCAO) or
photothrombotic brain lesion in the sensorimotor
cortex produce large unilateral strokes in rats, which
lead to deficits in skilled forelimb use, for example
when reaching food pellets [138, 139]. As in humans,
functional deficits persist and the spontaneous re-
covery of motor functions after large strokes is very
limited. However, this recovery was greatly in-
creased after treatment with anti-Nogo-A antibodies
[109, 140, 141] or with NgR receptor antagonists
[110] in rats. Control animals reached about 50% of
the preinjury performance level in tests that assess
the skilled forelimb use. In contrast, Nogo-A-anti-
body- or NgR-antagonist-treated animals recovered
up to 80–100%.
The spontaneous functional improvements after
stroke probably involve the opposite intact hemi-
sphere, which compensates for the loss of the infarcted
cortical area. Several clinical and experimental studies
found that plastic changes in the opposite hemisphere
can facilitate motor recovery: in patients who are
recovering from large strokes, movements of the
paralyzed limb produce an ipsilateral activation of the
intact sensorimotor cortex, which is not observed in
healthy control subjects [142–145]. Similar changes in
cortical activation are found after MCAO or unilat-
Figure 3. Functional recovery of skilled forelimb/hand use after high CST lesions in the rat (a) and the macaque monkey (b) with and
without anti-Nogo-A antibody treatment. (a) Pellet-reaching task. Intact rats require approximately 75 s to grasp and eat 20 food pellets
from a smooth surface (preoperative baseline). Forty-two days after a unilateral CST transection at the level of the pyramid
(pyramidotomy), control-antibody-treated rats (white bars) required significantly more time to grasp 20 pellets with their impaired
forelimb compared to the preoperative baseline. In contrast, anti-Nogo-A-antibody-treated animals (black bars) recovered to a
performance level that did not differ from the preoperative baseline, indicating that the treatment had lead to a substantial functional
recovery of precise forelimbusage. Error bars indicate standard error; *p < 0.05.Adaptedby permission fromNatureNeuroscience (1998)
vol. 1, pp. 124–131, copyright (1998)Macmillan Publishers Ltd. (b)Quantitative assessment of hand dexterity after a unilateral spinal cord
lesion at the C7/8 level, aimed at interrupting themain lateral CST.Macaquemonkeys were trained to grasp food pellets from horizontally
and vertically oriented slots. Immediately after the SCI, their ability to grasp food pellets was severely impaired. Thereafter, the animals
recovered partially, reaching a plateau within 30–60 days after injury. For analysis, the average score over 10 days after a stable
performance level had been reached (within 30–60 days after injury) was related to the average score over 10 prelesion testing days. The
recovery in percentage relative to the prelesion baseline is plotted against the lesion size (percentage hemicord lesion). In anti-Nogo-A-
antibody-treated monkeys (black squares), the recovery was complete (or nearly so) irrespective of lesion size, whereas in control-
antibody-treatedmonkeys (white squares) the functional recoverywas incomplete and appeared to correlate inversely with the lesion size.
Adapted with permission from Nature Medicine (2006) vol. 12, pp. 790–792, copyright (2006) Macmillan Publishers Ltd.
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eral cortical ablation in rats [146–148]. Furthermore,
in the unmyelinated CNS of newborn rats, unilateral
lesions of the sensorimotor cortex led to a substantial
increase of contralesional corticofugal projections
that cross the midline to innervate denervated motor
nuclei in the brainstem and spinal cord [149–153],
indicating that the contralesional cortex might take
over functions of the injured cortex.
In contrast, adult animals with fully myelinated
corticoefferent projections show no or only a minor
increase in collateral sprouting of the intact cortico-
spinal tract across the midline after stroke. However,
after neutralizing Nogo-A or blocking NgR in adult
rats, the collateral sprouting to the denervated side is
greatly increased, mimicking the results gained in
newborn animals. The number of corticostriatal fibres
projecting from the intact cortex to the contralateral
dorsolateral striatum was increased in anti-Nogo-A-
antibody-treated rats compared to control animals
[154]. In the mesencephalon, the ipsilesional red
nucleus, which had lost its ipsilateral cortical afferents,
received new, crossed afferents from the intact con-
tralateral cortex [109, 110, 140, 155]. Likewise, the
basilar pontine nuclei received more fibres from the
intact cortex [140]. At the level of the cervical spinal
cord, the number of midline-crossing corticospinal
fibres originating from the intact sensorimotor cortex
increased significantly [141] and the innervation of the
ispilesional medial motoneurons was augmented
[156].
In addition to these changes in corticofugal projec-
tions, the dendritic arbours of layer V pyramidal
neurons were observed to be altered too: after
unilateral MCAO, the contralateral apical and basilar
dendrites in Nogo-A-antibody-treated rats had a
greater degree of arborization and higher numbers
of spines than those of control-antibody-treated rats
[157].
Taken together these results suggest that the intact
contralesional cortex can gain control over areas
denervated by the unilateral cortical lesion. The intact
hemisphere forms new and detour connections by
sprouting into denervated subcorticalmotor areas and
by contacting other descending tracts that were not
affected by the cortical lesion, like the rubrospinal
tract. In fact, after unilateral cortical aspiration,
electrical stimulation of the intact contralesional
cortex resulted in increased activation of ipsilateral
forelimb muscles in Nogo-A-antibody-treated ani-
mals [158].
Plastic changes are likely to be more widespread and
not restricted to the contralesional side. Additional
plastic changes take place, for example, in the cortical
area adjacent to the infarct and the premotor areas
may also be important for the restitution of proper
motor functions, especially after smaller lesions [159].
It is probable that blockingNogo-A function increases
spontaneous plastic changes throughout the CNS and
thereby improves the functional recovery.
Do the observed anatomical changes account for the
functional recovery?
Achieving successful, i.e. functionally meaningful,
regeneration is immensely difficult. New fibres have
to integrate into existing, albeit dysfunctional circui-
tries and accurately connect to appropriate target
neurons. Connecting to wrong targets might lead to
malfunction with severe consequences, e.g. neuro-
genic pain, spasticity or epilepsies. Pain and spasticity
are common sequelae of SCI and have been associated
with erroneous connections that form in the injured
spinal cord [160–163].
Proving a causal relationship between plastic anatom-
ical changes and functional improvements is complex
and challenging. One way to demonstrate that sprout-
ing and regeneration do account for the enhanced
recovery of functions are relesion experiments where-
by newly grown connections are selectively destroyed.
The concurrent loss of the regained functions would
indirectly prove their specific contribution. Bregman
et al. [10] showed that the complete removal of the
sensorimotor cortex abolished functional improve-
ments after a large mid-thoracic hemisection follow-
ing anti-Nogo-A antibody treatment. Removing re-
generated raphespinal projections with a neurotoxin
that selectively kills serotonergic neurons (5,7-dihy-
droxytryptamine) partly abolished the functional
recovery seen in NgR knockout mice [33]. Although
theoretically convincing, relesion experiments have
an inherent danger of producing false-positive results:
selective transection of only the regrown fibres is
rarely possible; most lesions are large, damage other
pathways and cause a short-term conduction block by
oedema and inflammation.
Another approach to prove the functionality and
contribution of new connections are electrophysio-
logical experiments. Microstimulation of the rewired
rubrospinal tract, which normally does not directly
innervate motoneurons projecting to proximal fore-
limbmuscles, elicited short-latency electromyography
responses in these muscles, suggesting that direct
functional connections were formed [164]. Similarly,
transcranial magnetic stimulation of corticospinal
motoneurons after an incomplete thoracic lesion
showed an increased activation of hindlimb muscles
after blockade of NgR [133].
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Translating experimental interventions in spinal cord
research into clinical studies
A prerequisite for translating a new therapeutic
approach to treat SCI from rodents to humans are
studies with non-human primates [165]. Their nervous
system is more like ours and may react differently to
interventional therapies than that of rodents. The
CST, for example, has a different anatomy and is more
important in monkeys and humans than in rats.
Furthermore, the tissue reaction in response to a
lesion and the time course of regenerative processes
may be different from rodents. Most importantly,
monkeys, like humans, are very dexterous in using
their hands and fingers and can be trained to do
complex behavioural tasks allowing a more refined
assessment of motor function. In laboratory maca-
ques, which interact with scientist and animal care-
takers very closely during extended behavioural
experiments, it is also easier to detect potential side
effects of Nogo-A inactivation like pain, spasticity,
neuropsychiatric phenomena or changes in social
behaviour.
A recent study with 12 adult macaque monkeys has
confirmed the efficacy of Nogo-A antibody treatment
after SCI in primates [136]. A unilateral cervical
hemisection at C7 led to a substantial loss of ipsilateral
manual dexterity. Motor functions in the affected
hand, assessed with different tests of dexterity, recov-
ered faster and to a larger extent in anti-Nogo-A-
antibody-treated animals (Fig. 3b). No signs of pain or
any other side effects were detected. Anatomically,
regenerative sprouting of CST axons was observed
rostral to the lesion [166].
Translating these experimental findings into clinical
studies faces several challenges. The incidence of SCI
is low and therefore requires a multi-centre study
design to obtain a sufficient number of treated
patients. This in turn requires a high level of stand-
ardization of protocols between medical centres for a
precise diagnosis and the assessment and follow-up of
the recovery process. As the functional recovery is a
multifaceted process, clinical tests (muscle strength,
sensory functions, extent of neurological deficits,
neurological level of injury), functional evaluations
(walking capacity, hand dexterity, bladder control,
ability to live independently) and neurophysiologic
assessments (motor and somatosensory evoked po-
tentials) will have to be combined to evaluate
accurately the outcome of interventional therapies
[167].
Different spinal levels and variable lesion anatomy
imply that the population of spinal-cord-injured
patients is very heterogeneous with respect to func-
tional deficits and expected functional recovery. This
highlights the importance of standardizing the initial
clinical and neurophysiological examinations that can
reliably estimate the expected outcome and monitor
effects of the treatment.
Effective treatment of acute diseases often requires
prompt initiation of therapeutic interventions if they
are to be successful. Indeed, if the onset of anti-Nogo-
A antibody application after SCI is delayed for 1 or 2
weeks, the therapy is less effective in rats [168].
Accumulation of inhibitory CSPGs around the scar in
the days following an injury may prevent axons from
growing through or around the spinal cord lesion site.
Alternatively or in addition, neurons deprived of their
target-derived trophic support can become atrophic
and unresponsive to neutralization of Nogo-A.
A future treatment regime for patients with severe
SCI will probably require a multidisciplinary ap-
proach. After medical and surgical stabilization of the
acutely injured patient, the interventional therapies
may involve reagents to overcome myelin inhibition,
combined with neurotrophic factors to prevent neuro-
nal atrophy and stimulate growth, and treatments that
can reduce the growth-suppressive properties of the
glial scar. Intensive rehabilitative training pro-
grammes will support activity-dependent plastic proc-
esses in the CNS and help the patient to regain
independence.
A multicentre clinical trial for humanized Nogo-A
antibodies in acute SCI is now ongoing in several
countries.
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